BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31911904)

  • 1. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance.
    Wang G; Ning FY; Wang JH; Yan HM; Kong HW; Zhang YT; Shen Q
    World J Clin Cases; 2019 Dec; 7(24):4234-4244. PubMed ID: 31911904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of SIL-2R in Patients with Multiple Myeloma and Its Clinical Significance].
    Lin P; Lin XR; Liu QL; Zhang XY; Chen GW; Xie RT; Zhang YL; DU XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1797-1802. PubMed ID: 36476906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
    Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
    [No Abstract]   [Full Text] [Related]  

  • 8. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].
    Wang Y; Yue LL; Zeng PY; Wu CY; Han Y; Song Y; Jin QQ; Jiang HY; Chai Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1779-1784. PubMed ID: 36476903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J; Wu XB; Zhou Y; Wang X; Chen JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
    Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
    [No Abstract]   [Full Text] [Related]  

  • 13. [Correlation between Serum Interleukin-33, β
    Wang SY; Qiu DB; Fan CH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):788-793. PubMed ID: 37356941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma.
    Liu M; Zhang JY
    World J Clin Cases; 2023 Aug; 11(24):5643-5652. PubMed ID: 37727707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
    Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
    Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.